A Phase 2 interventional study of Fludarabine and Busulfan in Hematologic Malignancy, Acute Leukemia and Remission, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged Up to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing fludarabine in Hematologic Neoplasms — 11 open to participants now, 12 under way, none of them phase 3. fludarabine · Hematologic Neoplasms.
Among the 41 studies testing fludarabine in Hematologic Neoplasms, this one is the 9th largest by planned enrollment, is one of 3 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 32nd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →11 of the 41 studies testing fludarabine in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Chinese PLA General Hospital · Sites in China
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages up to 60
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: Up to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 24 · Phase 3 1 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 32 across the 41 interventional studies. Of the 22 that completed or were terminated, 15 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 41 have an industry lead sponsor. The 10 most frequent:
Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.
Masonic Cancer Center, University of Minnesota has 9 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing fludarabine in Hematologic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06807606M.D. Anderson Cancer CenterOptimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation | 2027-11-30 |
| NCT05735717Masonic Cancer Center, University of MinnesotaMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing fludarabine in Hematologic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Fludarabine · Drug: Rituximab · Drug: Levetiracetam · Biological: Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Fludarabine · Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam
Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia. , Closed to Accrual
Drug: Fludarabine · Drug: Busulfan · Drug: Melphalan · Drug: Rituximab · Drug: Levetiracetam
Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Fludarabine · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin
Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/BU/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Fludarabine · Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin
ATG/Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.
Drug: Fludarabine · Drug: Busulfan · Drug: Melphalan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin
Patients will be treated on the most medically appropriate regimen with a preference for ATG/BU/CY Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin · Drug: Cyclophosphamide
Patients will be treated on the most medically appropriate regimen with a preference for ATG/CY/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin · Drug: Cyclophosphamide
Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
Melphalan 50 mg/m2 IV on days -4 to -2
200 mg/m2 intravenous given once on day-1
As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
Also known as: Keppra
Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.
Also known as: ATG
Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2
Determine the rate of GVHD after alpha beta TCR depletion
GVHD incidence after treatment.
Time frame: 100 days
Transplant engraftment
Monitor median rate of engraftment by 42 days.
Time frame: 42 days
Graft Failure
Determine the rate of graft failure by day 100 (defined as lack of achievement of an ANC \>=500/mL with associated pancytopenia)
Time frame: 100 days
Non-relapse mortality (NRM)
Determine the incidence of non-relapse mortality (NRM) at 100 days and 1 year
Time frame: 12 months
Overall survival (OS)
Number of participants experiencing progression free survival at one year follow up
Time frame: 12 months
Plan to share: No — For the purposes of data and safety monitoring, this study is classified as high risk (investigator initiated under an IND). Therefore the following requirements will be fulfilled: The Masonic Cancer Center Data and Safety Monitoring Council (DSMC) will review the study's progress at least quarterly. The PI will comply with at least twice yearly monitoring of the project by the Masonic Cancer Center monitoring services. The PI will oversee the submission of all reportable adverse events per the definition of reportable in Section 11.5 to the Masonic Cancer Center's SAE Coordinator, the University of Minnesota IRB, and the FDA.
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Nov 2027, 54 months after the start.
Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 54 months is close to that.
Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Busulfan · Melphalan · Thymoglobulin · Cyclophosphamide
Masonic Cancer Center, University of Minnesota →